Related Experiment Videos
Antitryptic property of cancer-related glycoprotein EDC1
Cancer Research
|February 1, 1978
Abstract:
Cancer-related urinary glycoprotein EDC1 inhibits the action of trypsin and chymotrypsin on casein and synthetic substrates. The amino acid and carbohydrate compositions of EDC1 are different from those reported for pregnancy-related urinary trypsin inhibitors.
Insights
Cancer-related urinary glycoprotein EDC1 inhibits trypsin and chymotrypsin. Its composition differs from pregnancy-related urinary trypsin inhibitors, suggesting a distinct role in cancer.
Area of Science:
- Biochemistry
- Oncology
- Proteomics
Background:
- Urinary trypsin inhibitors play roles in various physiological processes.
- Cancer can alter protein expression and function in the urinary system.
Purpose of the Study:
- To characterize the cancer-related urinary glycoprotein EDC1.
- To investigate the enzymatic inhibitory activity of EDC1.
- To compare EDC1 with known urinary trypsin inhibitors.
Main Methods:
- Biochemical assays to determine enzymatic inhibition.
- Amino acid and carbohydrate composition analysis.
- Comparison with established urinary trypsin inhibitor data.
Main Results:
- EDC1 demonstrates inhibitory activity against trypsin and chymotrypsin.
- EDC1's amino acid and carbohydrate profiles are distinct.
- These compositional differences set EDC1 apart from pregnancy-related inhibitors.
Conclusions:
- EDC1 is a novel cancer-related urinary glycoprotein with trypsin inhibitory functions.
- Its unique composition suggests a specific role in cancer pathophysiology.
- Further research is warranted to elucidate EDC1's precise function in cancer.